tak-580
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 5, 2016 (NCT02723006)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
BRAF inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mln2480
- tak-580
- tak-580
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03429803 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2018 | Day One Biopharmaceuticals, Inc., Harvard University, National Cancer Institute (NCI), Team Jack Foundation, The Pacific Pediatric Neuro-Oncology Consortium |
| NCT02723006 | Phase 1 | Jul 5, 2016 | Millennium Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Millennium Pharmaceuticals | For profit | 1 | 1 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| Team Jack Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The Pacific Pediatric Neuro-Oncology Consortium | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1